Pfs230D1-EPA

Pfs230D1-EPA is a recombinant protein-based malaria transmission-blocking vaccine candidate. It consists of domain 1 of the *Plasmodium falciparum* gamete surface antigen Pfs230 (Pfs230D1) chemically conjugated to EPA, a nontoxic mutant of exoprotein A from *Pseudomonas aeruginosa*. The vaccine is designed to induce antibodies that block the sexual stage development of *P. falciparum* in mosquitoes, thereby preventing malaria transmission. Its mechanism relies on eliciting complement-dependent functional antibodies that target the parasite's gamete surface, leading to lysis and inhibition of oocyst formation in mosquitoes. Clinical trials have shown that Pfs230D1-EPA formulated with adjuvants such as Alhydrogel or AS01 induces potent transmission-reducing activity in humans and nonhuman primates, with higher efficacy observed compared to earlier candidates like Pfs25-EPA[1][2][4][5]. The vaccine has been developed primarily by public sector research organizations for use alone or potentially in combination with other antigens as part of broader malaria elimination strategies.

Other names

Pfs230D1M-EPAPfs-230D1M-EPAPfs 230D1M-EPA